Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | BCL9 | O00512 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13551971 | 0.87 | GAA (0.45) | MAPTGAAHPGDKMT2AALDH1A1 | |
| SCHEMBL12644466 | 0.85 | MAPT (0.44) | MAPTGAAHPGDKMT2AALDH1A1 | |
| SCHEMBL13551997 | 0.85 | MAPT (0.46) | MAPTGAAHPGDKMT2AALDH1A1 | |
| SCHEMBL12644427 | 0.84 | TTR (0.46) | MAPTGAAHPGDKMT2AALDH1A1 | |
| SCHEMBL12644191 | 0.84 | ALDH1A1 (0.39) | MAPTGAAHPGDKMT2AALDH1A1 | |
| SCHEMBL12644429 | 0.84 | PTGS1 (0.54) | MAPTHPGDKMT2AALDH1A1MEN1 | |
| SCHEMBL13551999 | 0.83 | HGFAC (0.46) | MAPTGAAHPGDKMT2AALDH1A1 | |
| SCHEMBL12643999 | 0.83 | MAPT (0.42) | MAPTGAAHPGDKMT2AALDH1A1 | |
| SCHEMBL12644214 | 0.83 | KMT2A (0.55) | MAPTGAAHPGDKMT2AALDH1A1 | |
| SCHEMBL12644451 | 0.82 | MAOB (0.45) | MAPTKMT2AALDH1A1MEN1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771321-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771321-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2017-07-06 | — | — | US | disclosed |
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2014-11-13 | — | — | US | disclosed |
| US-8703815-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703815-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-25 | — | — | US | disclosed |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | TTR, TTPA, APOB | MAPT 29/4885GAA 1719/4885HPGD 3426/4885 |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | TTR, TTPA, APOB | MAPT 29/4885GAA 1719/4885HPGD 3426/4885 |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | TTR, TTPA, APOB | MAPT 29/4885GAA 1719/4885HPGD 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.